EyePoint

EyePoint Shares Outstanding

The The number of shares of EyePoint (EYPT) as of Oct 18, 2026 is 56.30 M. In the previous year, The number of shares was 56.30 M — a change of 0.00% (lower).

Shares Outstanding

56.30 M

YoY

0.00%

Last updated:

In 2025, EyePoint had 56.30 M outstanding stocks, a 0.00% change from the 56.30 M stocks in the previous year.

The EyePoint Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2023
56.30 M USD
Jan 1, 2024
56.30 M USD
Jan 1, 2025
56.30 M USD
Jan 1, 2026 (e)
83.03 USD
Jan 1, 2027 (e)
83.03 USD
Jan 1, 2028 (e)
83.03 USD
Jan 1, 2029 (e)
83.03 USD
Jan 1, 2030 (e)
83.03 USD
The EyePoint Shares Outstanding history
YEARShares OutstandingYoY
est83.030.00%
est83.030.00%
est83.030.00%
est83.030.00%
est83.03-100.00%
56.30 M0.00%
56.30 M0.00%
56.30 M0.00%
56.30 M0.00%
56.30 M0.00%
56.30 M0.00%
56.30 M0.00%
56.30 M0.00%
56.30 M0.00%
56.30 M0.00%
56.30 M0.00%
56.30 M+2.09 B%
2.70+15.69%
2.33+11.99%
2.08+12.26%
1.85+1.17%
1.83+0.30%
1.83-0.01%
1.83+83.03%
1.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EyePoint Number of shares

EyePoint shares outstanding

The number of shares of EyePoint was 83.03 M in 2025. This indicates how many shares EyePoint is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2023
42.17 M Stocks
Jan 1, 2024
64.56 M Stocks
Jan 1, 2025
83.03 M Stocks
Jan 1, 2026 (e)
83.03 M Stocks
Jan 1, 2027 (e)
83.03 M Stocks
Jan 1, 2028 (e)
83.03 M Stocks
Jan 1, 2029 (e)
83.03 M Stocks
Jan 1, 2030 (e)
83.03 M Stocks

EyePoint Stock analysis

What does EyePoint do? EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and marketing of innovative products targeting medical and eye-related conditions. The company was founded in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals has a diverse portfolio of products focused on the treatment of eye diseases. This includes products for the treatment of retinal diseases such as diabetic retinopathy, macular degeneration, and retinal vein occlusions, as well as products for preventing postoperative infections and relieving pain after eye surgeries. The business model of EyePoint Pharmaceuticals is based on the development and marketing of drugs and technologies tailored to the needs of patients and physicians in the field of ophthalmology. The company aims to improve patients' quality of life by offering innovative, safe, and effective products of the highest quality. One of EyePoint Pharmaceuticals' key technologies is the Durasert technology, which allows for controlled release of drugs over an extended period of time. This technology is utilized in many of the company's products, such as the Iluvien implant for treating diabetic retinopathy and macular degeneration. The company operates in various sectors, including ophthalmology, pain management, and ophthalmology. Each of these sectors has its own products and technologies tailored specifically to the needs of patients and physicians in those areas. A significant factor in EyePoint Pharmaceuticals' business model is partnerships with other companies and organizations that support collaboration in the development and marketing of new products. One such partnership is the joint venture with Ocumension Therapeutics, which aims to market EyePoint Pharmaceuticals' products in the Asian market. Overall, the company has introduced a variety of innovative products to the market that have had a significant impact on ophthalmology. These include products such as the Ozurdex implant for treating macular degeneration and uveitis, as well as the Dexycu injection for preventing postoperative inflammation and pain. In recent years, the company has made progress in the development of drugs for retinal diseases such as diabetic retinopathy and retinal vein occlusions. One such development is the Yutiq implant, specifically designed to slow the progression of diabetic retinopathy. Overall, EyePoint Pharmaceuticals has a significant influence on ophthalmology and plays a crucial role in the development of innovative products and technologies to improve patients' quality of life. The company will continue to play an important role in the medical industry by focusing on the development and marketing of products targeting specific needs of patients and physicians in the field of ophthalmology. EyePoint is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating EyePoint's Shares Outstanding

EyePoint's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in EyePoint’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding EyePoint’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in EyePoint’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about EyePoint stock

The number of shares of EyePoint is 56.30 M in 2025.

The number of shares of EyePoint changed from 56.30 M to 56.30 M, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of shares EyePoint since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — EyePoint

All Key Metrics — EyePoint